|
ACIP has released updated COVID-19 vaccine guidance (as of May 27, 2025). These updates do not change current recommendations or how patients access the vaccine:
-
Children 6 months - 18 years: The Child and Adolescent Immunization Schedule now calls for shared clinical decision-making regarding COVID-19 vaccination for all children and adolescents aged 6 months through 17 years, including those who are moderately or severely immunocompromised. Any of these children may be vaccinated after a shared clinical decision with their healthcare provider. COVID-19 vaccines remain available through MIP - no changes to VFC.
-
Adults: No changes were made to recommendations for COVID-19 vaccination of adults who are not pregnant and age 18 years and older.
-
Pregnancy: The CDC has removed its recommendation for updated COVID-19 vaccines during pregnancy and lactation, however, the American College of Obstetricians and Gynecologists (ACOG) continues to recommend the use of updated COVID-19 vaccines for pregnant and lactating people. Any currently authorized COVID-19 vaccine can be given to pregnant, recently pregnant or lactating individuals. Providers should discuss vaccination options that are most appropriate for the individual.
-
Pharmacies - May continue routine vaccines and use shared clinical decision - making for ages 2 and older.
Child and Adolescent Schedule
Adult Schedule
Additional educational materials and updates from the Maine Immunization Program will be distributed as they become available.
Children’s Hospital of Philadelphia (CHOP) created multiple vaccines and disease infographics for children and adults that can be printed or ordered from CHOP for your clinics.
The Vaccines During Pregnancy: Timing and Notes About Protection (infographic): PDF | PNG is also available describing which vaccines are recommended during pregnancy. Prenatal care providers may find the Making Vaccine Decisions During Pregnancy: What to Know article helpful when offering vaccine recommendations to their pregnant patients. |
To ensure uninterrupted vaccine shipments, please complete these MIP requirements on time:
By July 1, 2025:
-
Provider Agreement: Complete in ImmPact. Sites without an approved agreement will not receive vaccine shipments.
-
Vaccine Need: Update in ImmPact to reflect patient populations served in the past 12 months.
-
Data Logger Certificates: No submission needed for 2025 -- MIP will obtain these automatically.
By July 31, 2025:
-
VFC Annual Training & Post-Test: All primary and secondary vaccine coordinators must complete the training and post-test. New coordinators added between June 1 -30 who have not completed this must contact ImmunizeME.DHHS@maine.gov for a paper copy.
Lunch & Learn Webinars: MIP will host quarterly webinars for new or transitioning coordinators, plus 1:1 training by request. Meeting invites will be distributed through upcoming communications.
All influenza will be expiring June 30, 2025. Please ensure that the vaccine has been removed from your storage unit and returned to McKesson. Please contact MIP’s Vaccine Management (207-287-3006) for a return authorization.
On May 29, CDC released updated VISs for and . Changes incorporate recommendations for the routine use of PCV for adults age 50 years and older (previously 65 years) and the limited use of PPSV23. The updated VISs refer to PCVs generally and no longer reference specific PCV products.
The use of the updated VISs should begin immediately. If you use Immunize.org’s on our website, you can keep using them. These QR code documents automatically link to the updated VISs and ensure you are always accessing the current official version.
CDC has added new resources to the Be Ready for Measles Toolkit:
-
Adult MMR vaccination decision tree for healthcare providers summarizing ACIP and CDC MMR vaccine recommendations for non-pregnant adults aged 19 years and older. Providers can use this visual aid to make decisions about MMR vaccination for adults.
-
Summer camp tools: Camp administrators can use these tools to help prepare for and respond to measles cases.
We've received reports of providers discarding doses of BEXSERO due to the presence of air bubbles in the syringe. GSK has shared updated guidance to address this issue and assist providers in handling these situations appropriately. If your site administers BEXSERO, please review and share this information to help reduce unnecessary vaccine wastage.
Bexsero Air Bubble in OnePFS Presentation
Bexsero Prescribing Information PI |
